Reveal Biosciences Announces the Launch of imageDx™ A Unique Cloud-based AI Pathology Platform

imageDx™ platform creates a new generation of Pathology Intelligence™

(SAN DIEGO, CA. Jan. 12, 2021) — Reveal Biosciences, Inc., an established AI data provider, has developed a powerful and dynamic SaaS pathology platform called imageDx™. Equipped with a full service automated histopathology lab, Reveal is uniquely positioned as a “one stop solution” for generating quantitative data from tissue samples with imageDx™ at its core. The imageDx™ platform provides cloud-based image management and AI-powered digital assays to a wide user base. 

imageDx™ is available for small to large teams enterprise wide. To date, imageDx™ has delivered data to over 400 leading bio-pharmaceutical companies globally. This includes 7 out of the top 10 Pharmaceutical Companies. 

Users upload images onto the imageDx™ platform for remote collaboration and large scale analysis. Next, an integrated quality control algorithm called imageQC™ is deployed across all images to assess focus, tissue and slide artifacts, and color profile to ensure the accuracy of data generated. Users gain access to a portfolio of digital assays on the platform spanning a wide variety of therapeutic areas to generate standardized data at scale. Data visualization capabilities allow users to view their quantitative data alongside the corresponding whole slide images. As a cloud-based workspace, imageDx™ enables secure user-to-user image and data collaboration, enhanced automated and manual annotations and sophisticated labelling ontologies.

The imageDx™ platform is compatible with all leading pathology image formats including the FDA approved scanners from Leica and Phillips.  

The platform provides a powerful pathology solution for both pre-clinical and clinical contexts.  With digital assays covering areas such as NASH, Oncology, Neuroscience, Fibrosis and Inflammation, Reveal also develops custom AI models to generate specific data points at speed using a unique proprietary pipeline architecture.  

“We are excited to launch imageDx™ knowing the difference it has already made to the way pathology data is generated. The power of AI to predict outcomes, stratify patient groups, and detect small changes in tissue morphology that can not be seen by the human eye, has huge potential to impact precision medicine and companion diagnostics,” said Claire Weston, PhD, CEO at Reveal Biosciences.

About Reveal Biosciences

Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research and improve patient outcomes globally.  Reveal’s imageDx™ SaaS pathology platform combines cutting edge artificial intelligence (AI) with traditional histopathology to transform tissue biology into actionable insights. imageDx™ provides AI data analytics and cloud-based whole slide image management to Life Sciences and Healthcare.

Reveal has its own fully automated laboratory and experienced scientists, providing histopathology, immunohistochemistry (IHC) and in situ hybridization (ISH) expertise for a wide range of pharmaceutical, biotech, academic, and government institutions. With a world class team of data and research scientists focused on addressing some of the biggest problems in healthcare, Reveal has developed a pipeline of AI-based digital assays for preclinical research, clinical trials, and decision support. 

Reveal Biosciences is Headquartered in San Diego, California, and currently serves clients across the United States, United Kingdom, Europe, & the Asia Pacific.

Contact us at [email protected]

Share Article

Pathology Revealed

Sign up to receive updates on the latest AI-powered pathology breakthroughs, access digital pathology resources, and more.